FAQ on Quantum BioPharma Ltd.'s Appointment of Kevin Malone as Board Advisor

Who is Kevin Malone and what is his background?

Kevin Malone is a seasoned financial advisor with over 40 years of family experience in wealth management, known for his work in market pattern recognition and his outspoken stance against trading manipulation. He is the founder of Malone Wealth and champions financial literacy and advocates against naked short selling.

Why did Quantum BioPharma appoint Kevin Malone as a Board Advisor?

Quantum BioPharma appointed Kevin Malone due to his expertise in financial markets and his advocacy against trading manipulation, which aligns with the company’s shareholder protection values and its focus on developing therapeutic solutions for challenging disorders.

What is Quantum BioPharma Ltd. focused on?

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development.

What is Lucid-MS and what is its significance?

Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It is being developed through its wholly owned subsidiary, Lucid Psycheceuticals Inc.

UNBUZZD is a product invented by Quantum BioPharma, which spun out its OTC version to Celly Nutrition Corp. Quantum BioPharma retains ownership of 25.71% of Celly Nutrition and receives royalty payments from sales of UNBUZZD, along with the rights to develop similar products for pharmaceutical and medical uses.

Where can I find more information about Quantum BioPharma Ltd.?

The latest news and updates relating to Quantum BioPharma Ltd. (QNTM) are available in the company’s newsroom at https://ibn.fm/QNTM.

What are the terms of the agreement between Quantum BioPharma and Celly Nutrition regarding UNBUZZD?

The agreement includes royalty payments of 7% of sales from UNBUZZD until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.

InvestorWire is a specialized communications platform that provides advanced wire-grade press release syndication for private and public companies and the investment community. It is part of the Dynamic Brand Portfolio at IBN, which delivered this announcement.

Summary